{"hands_on_practices": [{"introduction": "A core task in clinical practice is updating your assessment of a patient's risk based on new information. This exercise grounds this process in formal probability, using Bayes' theorem to connect the pre-test probability of disease to the post-test odds after a positive mammogram [@problem_id:4570685]. By working through the derivation, you'll gain a fundamental understanding of how to quantify the true meaning of a screening result.", "problem": "A population-based program for early detection of breast cancer offers digital mammography to average-risk women aged $50$ to $69$. Consider a representative woman with pretest probability (prevalence at the screening visit) of undiagnosed breast cancer $\\pi = 0.03$. The screening test has sensitivity $0.85$ and specificity $0.90$. The woman’s mammogram is positive.\n\nStarting from the definitions of sensitivity and specificity, and Bayes’ theorem relating $P(D|+)$, $P(+|D)$, $P(+|\\bar{D})$, $P(D)$, and $P(\\bar{D})$, derive an expression for the post-test odds $\\frac{P(D|+)}{1-P(D|+)}$ in terms of the pretest odds $O=\\frac{\\pi}{1-\\pi}$ and the positive likelihood ratio $LR^{+}$. Then compute the numerical value of the post-test odds for this scenario. Round your final numerical answer to $4$ significant figures and express it as a pure number (unitless odds).", "solution": "The user wants me to solve the following problem:\nA population-based program for early detection of breast cancer offers digital mammography to average-risk women aged $50$ to $69$. Consider a representative woman with pretest probability (prevalence at the screening visit) of undiagnosed breast cancer $\\pi = 0.03$. The screening test has sensitivity $0.85$ and specificity $0.90$. The woman’s mammogram is positive.\n\nStarting from the definitions of sensitivity and specificity, and Bayes’ theorem relating $P(D|+)$, $P(+|D)$, $P(+|\\bar{D})$, $P(D)$, and $P(\\bar{D})$, derive an expression for the post-test odds $\\frac{P(D|+)}{1-P(D|+)}$ in terms of the pretest odds $O=\\frac{\\pi}{1-\\pi}$ and the positive likelihood ratio $LR^{+}$. Then compute the numerical value of the post-test odds for this scenario. Round your final numerical answer to $4$ significant figures and express it as a pure number (unitless odds).\n\n### Step 1: Extract Givens\n- Population: Average-risk women aged $50$ to $69$.\n- Pretest probability of disease (prevalence): $\\pi = P(D) = 0.03$.\n- Test sensitivity: $P(\\text{test}+ | \\text{Disease}) = P(+|D) = 0.85$.\n- Test specificity: $P(\\text{test}- | \\text{No Disease}) = P(-|\\bar{D}) = 0.90$.\n- Test result: Positive ($+$).\n- Bayes' theorem relates: $P(D|+)$, $P(+|D)$, $P(+|\\bar{D})$, $P(D)$, and $P(\\bar{D})$.\n- Pretest odds: $O = \\frac{\\pi}{1-\\pi}$.\n- Task 1: Derive the expression for post-test odds $\\frac{P(D|+)}{1-P(D|+)}$ in terms of $O$ and the positive likelihood ratio $LR^{+}$.\n- Task 2: Compute the numerical value of the post-test odds, rounded to $4$ significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded in the principles of Bayesian statistics and epidemiology. The concepts of prevalence, sensitivity, specificity, and likelihood ratios are standard in medical diagnostics. The provided numerical values ($\\pi = 0.03$, sensitivity = $0.85$, specificity = $0.90$) are realistic for mammography screening in the specified demographic. The problem is well-posed, self-contained, and objective, providing all necessary information to perform the required derivation and calculation. There are no contradictions, ambiguities, or violations of scientific or mathematical principles.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete, reasoned solution will be provided.\n\n### Solution Derivation and Calculation\n\nLet $D$ be the event that a woman has breast cancer, and $\\bar{D}$ be the event that she does not. Let $+$ denote a positive mammogram result and $-$ denote a negative result.\n\nThe givens are:\n- Pretest probability of disease: $P(D) = \\pi = 0.03$.\n- Probability of no disease: $P(\\bar{D}) = 1 - P(D) = 1 - \\pi = 1 - 0.03 = 0.97$.\n- Sensitivity: $P(+|D) = 0.85$. This is the probability of a positive test given the woman has the disease.\n- Specificity: $P(-|\\bar{D}) = 0.90$. This is the probability of a negative test given the woman does not have the disease.\n\nThe problem asks for an expression for the post-test odds, which are the odds of having the disease given a positive test result. This is represented as $\\frac{P(D|+)}{P(\\bar{D}|+)}$. Note that since $P(D|+) + P(\\bar{D}|+) = 1$, we have $P(\\bar{D}|+) = 1 - P(D|+)$, so the post-test odds can also be written as $\\frac{P(D|+)}{1-P(D|+)}$.\n\nWe start with Bayes' theorem to find the post-test probability $P(D|+)$:\n$$P(D|+) = \\frac{P(+|D) P(D)}{P(+)}$$\nSimilarly, for the complementary event:\n$$P(\\bar{D}|+) = \\frac{P(+|\\bar{D}) P(\\bar{D})}{P(+)}$$\nThe ratio of these two probabilities gives the post-test odds:\n$$\\text{Post-test odds} = \\frac{P(D|+)}{P(\\bar{D}|+)} = \\frac{\\frac{P(+|D) P(D)}{P(+)}}{\\frac{P(+|\\bar{D}) P(\\bar{D})}{P(+)}} = \\frac{P(+|D) P(D)}{P(+|\\bar{D}) P(\\bar{D})}$$\nWe can rearrange this expression as a product of two ratios:\n$$\\text{Post-test odds} = \\left( \\frac{P(+|D)}{P(+|\\bar{D})} \\right) \\times \\left( \\frac{P(D)}{P(\\bar{D})} \\right)$$\nNow we identify the terms in this expression based on the definitions given in the problem statement.\n\nThe second term, $\\frac{P(D)}{P(\\bar{D})}$, is the ratio of the pretest probability of having the disease to the pretest probability of not having the disease. This is the definition of the pretest odds, $O$:\n$$O = \\frac{P(D)}{P(\\bar{D})} = \\frac{\\pi}{1-\\pi}$$\n\nThe first term, $\\frac{P(+|D)}{P(+|\\bar{D})}$, is the positive likelihood ratio, denoted as $LR^{+}$. It is the ratio of the probability of a positive test in a person with the disease (sensitivity) to the probability of a positive test in a person without the disease (false positive rate).\n$$LR^{+} = \\frac{P(+|D)}{P(+|\\bar{D})}$$\nThe numerator, $P(+|D)$, is the sensitivity. The denominator, $P(+|\\bar{D})$, is the false positive rate, which can be derived from the specificity:\n$$P(+|\\bar{D}) = 1 - P(-|\\bar{D}) = 1 - \\text{specificity}$$\nSubstituting these definitions back into the expression for Post-test odds, we get the desired relationship:\n$$\\frac{P(D|+)}{1-P(D|+)} = LR^{+} \\times O$$\nThis completes the derivation.\n\nNext, we compute the numerical value for the post-test odds.\n\nFirst, we calculate the pretest odds, $O$:\n$$O = \\frac{\\pi}{1-\\pi} = \\frac{0.03}{1 - 0.03} = \\frac{0.03}{0.97}$$\nSecond, we calculate the positive likelihood ratio, $LR^{+}$:\n- Sensitivity is given as $P(+|D) = 0.85$.\n- Specificity is given as $P(-|\\bar{D}) = 0.90$.\n- The false positive rate is $P(+|\\bar{D}) = 1 - P(-|\\bar{D}) = 1 - 0.90 = 0.10$.\n$$LR^{+} = \\frac{P(+|D)}{P(+|\\bar{D})} = \\frac{0.85}{0.10} = 8.5$$\nFinally, we compute the post-test odds using the derived formula:\n$$\\text{Post-test odds} = LR^{+} \\times O = 8.5 \\times \\frac{0.03}{0.97}$$\n$$\\text{Post-test odds} = \\frac{8.5 \\times 0.03}{0.97} = \\frac{0.255}{0.97} \\approx 0.2628865979...$$\nThe problem requires rounding the final answer to $4$ significant figures.\n$$\\text{Post-test odds} \\approx 0.2629$$\nThe post-test odds of the woman having breast cancer after a positive mammogram are approximately $0.2629$. This can be interpreted as the woman being about $0.26$ times as likely to have cancer as not to have it, or roughly a $1$ in $4.8$ chance of having the disease ($1 / (1+0.2629) \\approx 0.208$).", "answer": "$$\\boxed{0.2629}$$", "id": "4570685"}, {"introduction": "Choosing a screening test involves navigating the inherent trade-off between sensitivity and specificity, as a test that is better at finding true positives may also generate more false alarms. This practice problem models a realistic public health dilemma, asking you to calculate the net change in biopsies when one screening protocol is replaced by another with different performance characteristics [@problem_id:4570647]. This exercise provides a tangible way to measure the system-wide consequences of such a decision.", "problem": "A public health program is evaluating a proposed change to its mammography screening protocol for breast cancer. The current protocol uses a test with sensitivity $0.85$ and specificity $0.92$. The proposed test has sensitivity $0.90$ and specificity $0.88$. In the target screening population, the prevalence (pre-test probability) of undiagnosed breast cancer is $\\pi = 0.005$. Consider a screening cohort of $1{,}000$ independent individuals who each undergo exactly one screening test.\n\nUse only the core definitions of sensitivity, specificity, and prevalence, together with the law of total probability, to estimate the change in the expected number of biopsies when switching from the current test to the proposed test. Assume that every positive screening test leads directly to exactly one biopsy, and that negative screening tests lead to no biopsies. Treat expected counts as real-valued quantities.\n\nCompute the expected number of additional biopsies per $1{,}000$ screens when switching from the current test to the proposed test, and report the increase as a positive value (new minus current). Express your final result as a rate in biopsies per $1{,}000$ screens, rounded to three significant figures.", "solution": "The problem is valid as it is scientifically grounded in epidemiology, well-posed with sufficient and consistent data, and objectively stated. It presents a standard biostatistics calculation without any factual or logical flaws.\n\nLet $D$ be the event that a randomly selected individual from the screening population has undiagnosed breast cancer, and let $D^c$ be the complementary event that the individual does not have the disease. The prevalence, or pre-test probability of the disease, is given as $\\pi = P(D) = 0.005$. Consequently, the probability of an individual not having the disease is $P(D^c) = 1 - \\pi = 1 - 0.005 = 0.995$.\n\nLet $T$ be the event that a screening test result is positive. The problem states that the number of biopsies is equal to the number of positive screening tests. Therefore, the expected number of biopsies for a cohort of size $N$ is $E[\\text{biopsies}] = N \\times P(T)$. We need to calculate the change in this expected number when switching from the current test to the proposed test for a cohort of $N=1000$.\n\nThe overall probability of a positive test, $P(T)$, can be found using the law of total probability:\n$$P(T) = P(T|D)P(D) + P(T|D^c)P(D^c)$$\nThe conditional probability $P(T|D)$ is the sensitivity of the test, which we denote as $S$. The conditional probability $P(T^c|D^c)$ is the specificity of the test, denoted as $P_{spec}$. The term $P(T|D^c)$ is the probability of a false positive, which is equal to $1 - P(T^c|D^c) = 1 - P_{spec}$.\nSubstituting these definitions into the law of total probability gives the general formula for the probability of a positive test:\n$$P(T) = S \\cdot \\pi + (1 - P_{spec}) \\cdot (1 - \\pi)$$\n\nFirst, we calculate the probability of a positive test for the current protocol, denoted $P(T_c)$.\nThe givens for the current test are:\nSensitivity $S_c = 0.85$\nSpecificity $P_{spec,c} = 0.92$\n$$P(T_c) = S_c \\cdot \\pi + (1 - P_{spec,c}) \\cdot (1 - \\pi)$$\n$$P(T_c) = (0.85)(0.005) + (1 - 0.92)(1 - 0.005)$$\n$$P(T_c) = (0.85)(0.005) + (0.08)(0.995)$$\n$$P(T_c) = 0.00425 + 0.0796 = 0.08385$$\nThe expected number of biopsies for the current test per $1000$ screens is:\n$$E_c = N \\times P(T_c) = 1000 \\times 0.08385 = 83.85$$\n\nNext, we calculate the probability of a positive test for the proposed protocol, denoted $P(T_p)$.\nThe givens for the proposed test are:\nSensitivity $S_p = 0.90$\nSpecificity $P_{spec,p} = 0.88$\n$$P(T_p) = S_p \\cdot \\pi + (1 - P_{spec,p}) \\cdot (1 - \\pi)$$\n$$P(T_p) = (0.90)(0.005) + (1 - 0.88)(1 - 0.005)$$\n$$P(T_p) = (0.90)(0.005) + (0.12)(0.995)$$\n$$P(T_p) = 0.0045 + 0.1194 = 0.1239$$\nThe expected number of biopsies for the proposed test per $1000$ screens is:\n$$E_p = N \\times P(T_p) = 1000 \\times 0.1239 = 123.9$$\n\nThe change in the expected number of biopsies is the difference between the expected number for the proposed test and the current test, $\\Delta E = E_p - E_c$.\n$$\\Delta E = 123.9 - 83.85 = 40.05$$\nAlternatively, we can compute the difference directly:\n$$\\Delta E = N \\times (P(T_p) - P(T_c))$$\n$$\\Delta E = 1000 \\times [ (S_p - S_c)\\pi + ((1-P_{spec,p}) - (1-P_{spec,c}))(1-\\pi) ]$$\n$$\\Delta E = 1000 \\times [ (0.90 - 0.85)(0.005) + ( (1-0.88) - (1-0.92) )(0.995) ]$$\n$$\\Delta E = 1000 \\times [ (0.05)(0.005) + (0.12 - 0.08)(0.995) ]$$\n$$\\Delta E = 1000 \\times [ 0.00025 + (0.04)(0.995) ]$$\n$$\\Delta E = 1000 \\times [ 0.00025 + 0.0398 ]$$\n$$\\Delta E = 1000 \\times 0.04005 = 40.05$$\nThe problem asks for this value to be reported as a rate in biopsies per $1000$ screens, rounded to three significant figures.\nRounding $40.05$ to three significant figures gives $40.1$. This positive value represents an increase in the number of biopsies.", "answer": "$$\\boxed{40.1}$$", "id": "4570647"}, {"introduction": "Some of the most compelling arguments for screening come from observing a \"stage shift\"—more cancers being found at an early, more treatable stage. However, this apparent benefit can be misleading due to inherent biases like length bias and overdiagnosis. This advanced thought experiment uses a hypothetical model to demonstrate how a screening program can create a dramatic stage shift without any actual reduction in mortality [@problem_id:4570694]. Mastering this concept is crucial for critically evaluating the true effectiveness of a screening program beyond its surface-level statistics.", "problem": "A closed cohort of $N = 100{,}000$ women aged $50$ to $69$ years is observed over a fixed horizon of $T = 10$ years. The biological onset of breast cancer follows a constant incidence rate $\\lambda = 1.0 \\times 10^{-3}$ per woman-year. Each biological onset is independently one of two phenotypes: indolent with probability $q = 0.6$ and aggressive with probability $1 - q = 0.4$. Tumor growth is assumed to be monotone in size, with indolent tumors growing slowly and aggressive tumors growing rapidly; their mean preclinical sojourn times (time from biological onset to clinical detectability without screening) are $s_{i} = 6$ years (indolent) and $s_{a} = 1$ year (aggressive).\n\nStage at diagnosis is determined by a size threshold $d_{e}$: “early stage” if the tumor is detected at size $ d_{e}$ and “late stage” otherwise. In the pre-screening era, detection occurs only when a clinical threshold $d_{c}  d_{e}$ is reached; thus all clinically detected tumors are late stage. In the screening era, all women undergo regular mammography (first mention: Digital Mammography (DM)) that lowers the detection threshold to $d_{s}$ with $d_{s}  d_{e}$; as a result, tumors detected by screening are classified as early stage at the time of detection. Assume perfect adherence to screening and perfect sensitivity at the lowered threshold $d_{s}$, so that detection by screening occurs before clinical presentation whenever the tumor’s preclinical sojourn is positive.\n\nAssume the following mortality model: conditional on phenotype, the hazard of breast cancer death is constant in time and independent of the size at detection (thus, independent of stage at detection). For indolent tumors, the hazard is $\\mu_{i} = 0$ over the $T$-year horizon, yielding a zero probability of breast cancer death in $T$ years. For aggressive tumors, the hazard is $\\mu_{a}  0$, yielding a $T$-year breast cancer death probability equal to $1 - \\exp(-\\mu_{a} T)$. Suppose that for aggressive tumors $1 - \\exp(-\\mu_{a} T) = 0.8$ over $T = 10$ years.\n\nLength bias is present: among screen-detected tumors, the composition is weighted by preclinical sojourn time. In a steady-state screening regime, the probability that a randomly screen-detected case is of phenotype $\\text{type} \\in \\{i, a\\}$ is proportional to the product of its population fraction and its preclinical sojourn time; specifically, the indolent fraction among screen-detected tumors equals\n$$\n\\frac{q s_{i}}{q s_{i} + (1 - q) s_{a}}.\n$$\n\nUsing only foundational definitions of incidence, survival functions, and hazard rates, and the length-bias weighting above, analyze this cohort in the pre-screening and screening eras to:\n\n1. Derive the expected number of biological onsets over $T = 10$ years and their breakdown by phenotype.\n2. Explain, using the detection thresholds $d_{c}$, $d_{e}$, and $d_{s}$ and the length-bias relation, why the stage distribution shifts toward early stage after screening without implying a change in the death hazard.\n3. Compute the expected number of breast cancer deaths over $T = 10$ years in the pre-screening era.\n4. Compute the expected number of breast cancer deaths over $T = 10$ years in the screening era.\n5. Finally, compute the ratio $R$ of the $10$-year breast cancer mortality rate (per $100{,}000$ women) in the screening era to that in the pre-screening era. Express your final answer $R$ as an exact value without rounding and without units.", "solution": "The problem presents a stylized model of breast cancer incidence, detection, and mortality to analyze the effects of a screening program. The problem is validated as self-contained, scientifically grounded as a conceptual model, and well-posed. We proceed with a systematic solution to the five parts of the problem.\n\n**1. Expected Number of Biological Onsets and Phenotype Breakdown**\n\nThe cohort consists of $N = 100,000$ women observed over a period of $T = 10$ years. The total woman-years of observation is the product of the number of women and the observation time:\n$$\n\\text{Total Woman-Years} = N \\times T = 100,000 \\times 10 = 1,000,000\n$$\nThe biological onset of breast cancer is modeled as a Poisson process with a constant incidence rate of $\\lambda = 1.0 \\times 10^{-3}$ per woman-year. The expected number of biological onsets, $E[\\text{Onsets}]$, over the $T=10$-year horizon is the product of the total woman-years and the incidence rate:\n$$\nE[\\text{Onsets}] = (N \\times T) \\times \\lambda = (1,000,000 \\text{ woman-years}) \\times (1.0 \\times 10^{-3} \\text{ year}^{-1}) = 1000\n$$\nThus, we expect $1000$ new cases of breast cancer to arise biologically in the cohort over the $10$-year period.\n\nThese onsets are categorized into two phenotypes: indolent and aggressive.\nThe probability of a tumor being indolent is $q = 0.6$. The expected number of indolent onsets is:\n$$\nE[\\text{Indolent Onsets}] = E[\\text{Onsets}] \\times q = 1000 \\times 0.6 = 600\n$$\nThe probability of a tumor being aggressive is $1 - q = 0.4$. The expected number of aggressive onsets is:\n$$\nE[\\text{Aggressive Onsets}] = E[\\text{Onsets}] \\times (1 - q) = 1000 \\times 0.4 = 400\n$$\n\n**2. Explanation of Stage Shift**\n\nThe stage at diagnosis is determined by the tumor size relative to a threshold $d_e$. A tumor is \"early stage\" if its size at detection is less than $d_e$ and \"late stage\" otherwise. The problem provides a hierarchy of detection thresholds: $d_s  d_e  d_c$, where $d_s$ is the screening detection threshold and $d_c$ is the clinical detection threshold.\n\n- In the **pre-screening era**, detection occurs only upon clinical presentation, when the tumor reaches size $d_c$. Since $d_c  d_e$, all tumors detected in this era are diagnosed at a size greater than the early-stage threshold. Therefore, by definition, $100\\%$ of cancers diagnosed in the pre-screening era are classified as \"late stage\".\n\n- In the **screening era**, with perfect adherence and sensitivity, all tumors are detected by mammography when they reach the size threshold $d_s$. Since $d_s  d_e$, all tumors detected by screening are diagnosed at a size smaller than the early-stage threshold. Therefore, by definition, $100\\%$ of cancers diagnosed in the screening era are classified as \"early stage\".\n\nThe introduction of screening thus causes a definitional shift in the stage distribution from entirely late-stage to entirely early-stage.\n\nThis stage shift, however, does **not** imply a change in the death hazard. The model's central assumption is that the hazard of breast cancer death, $\\mu$, is conditional *only on the biological phenotype* (indolent or aggressive) and is explicitly \"independent of the size at detection (thus, independent of stage at detection)\".\n- For indolent tumors, the hazard $\\mu_i = 0$.\n- For aggressive tumors, the hazard is $\\mu_a  0$.\n\nThis means that a woman who develops an aggressive tumor faces the same mortality risk regardless of whether it is detected at size $d_s$ (and labeled \"early stage\") or at size $d_c$ (and labeled \"late stage\"). The screening program changes the diagnostic label but does not, according to this model, alter the intrinsic lethality of the disease.\n\nFurthermore, the **length-bias** phenomenon, as described, makes the screening program appear more effective than it is. The fraction of indolent (non-lethal) tumors among screen-detected cases is given by:\n$$\n\\frac{q s_{i}}{q s_{i} + (1 - q) s_{a}} = \\frac{0.6 \\times 6}{0.6 \\times 6 + 0.4 \\times 1} = \\frac{3.6}{3.6 + 0.4} = \\frac{3.6}{4.0} = 0.9\n$$\nThis shows that $90\\%$ of screen-detected cases are of the indolent type, which have a zero death hazard ($\\mu_i=0$). This is a significant enrichment compared to the underlying $60\\%$ incidence of indolent tumors. This effect, a form of overdiagnosis, means that screening preferentially finds cases with an excellent prognosis, creating a misleading impression of benefit that is separate from the stage shift.\n\n**3. Expected Number of Breast Cancer Deaths in the Pre-Screening Era**\n\nAccording to the model, breast cancer mortality is solely attributable to aggressive tumors, as the death hazard for indolent tumors is $\\mu_i = 0$.\nFrom Part 1, the expected number of aggressive biological onsets over the $10$-year period is $400$.\nThe problem states that for aggressive tumors, the $10$-year probability of death from breast cancer, $P(\\text{death}|\\text{aggressive})$, is $0.8$.\nThe total expected number of deaths is the product of the number of aggressive cancers and the probability of death for each case.\n$$\nE[\\text{Deaths}_{\\text{pre-screening}}] = E[\\text{Aggressive Onsets}] \\times P(\\text{death}|\\text{aggressive})\n$$\n$$\nE[\\text{Deaths}_{\\text{pre-screening}}] = 400 \\times 0.8 = 320\n$$\nIn the pre-screening era, we expect $320$ breast cancer deaths over the $10$-year horizon.\n\n**4. Expected Number of Breast Cancer Deaths in the Screening Era**\n\nThe introduction of screening does not change the underlying biological incidence of cancer. The expected number of indolent and aggressive onsets remains $600$ and $400$, respectively.\nThe core assumption of the model is that mortality risk is determined by phenotype alone and is independent of the mode or stage of detection. Therefore, the $10$-year death probability for a woman with an aggressive tumor remains $0.8$, even though her cancer is now detected earlier and labeled \"early stage\".\nThe calculation for the expected number of deaths is therefore identical to that of the pre-screening era:\n$$\nE[\\text{Deaths}_{\\text{screening}}] = E[\\text{Aggressive Onsets}] \\times P(\\text{death}|\\text{aggressive})\n$$\n$$\nE[\\text{Deaths}_{\\text{screening}}] = 400 \\times 0.8 = 320\n$$\nIn the screening era, we expect $320$ breast cancer deaths, the same as in the pre-screening era. This result highlights that, under the given assumptions, screening provides no mortality benefit.\n\n**5. Ratio of 10-Year Breast Cancer Mortality Rates**\n\nThe problem asks for the ratio $R$ of the $10$-year breast cancer mortality rate in the screening era to that in the pre-screening era. The rate is specified per $100,000$ women.\n\nThe mortality rate in the pre-screening era is the expected number of deaths divided by the cohort size, normalized per $100,000$ women:\n$$\n\\text{Rate}_{\\text{pre-screening}} = \\frac{E[\\text{Deaths}_{\\text{pre-screening}}]}{N / 100,000} = \\frac{320}{100,000 / 100,000} = 320 \\text{ per } 100,000\n$$\nThe mortality rate in the screening era is:\n$$\n\\text{Rate}_{\\text{screening}} = \\frac{E[\\text{Deaths}_{\\text{screening}}]}{N / 100,000} = \\frac{320}{100,000 / 100,000} = 320 \\text{ per } 100,000\n$$\nThe ratio $R$ is:\n$$\nR = \\frac{\\text{Rate}_{\\text{screening}}}{\\text{Rate}_{\\text{pre-screening}}} = \\frac{320}{320} = 1\n$$\nThe ratio of the mortality rates is $1$. This analytically confirms that, within this specific conceptual model, the screening program has no effect on breast cancer mortality.", "answer": "$$\\boxed{1}$$", "id": "4570694"}]}